Immutep (IMMP) details two ESMO 2025 posters in first line lung cancer

Rhea-AI Filing Summary

Immutep Limited filed a Form 6-K to furnish information about scientific presentations at a major oncology meeting. The filing notes an exhibit titled “Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer.”

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date as October 20, 2025

Commission File Number 001-35428

IMMUTEP LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

Level 32, Australia Square

264 George Street, Sydney

NSW 2000, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐   No ☒

If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 20, 2025

IMMUTEP LIMITED
By:		/s/ Marc Voigt
Name:		Marc Voigt
Title:		Chief Executive Officer

FAQ

What does Immutep (IMMP) report in this Form 6-K?

Immutep reports that it is furnishing an exhibit about two scientific posters at ESMO Congress 2025. These posters highlight the company’s focus on the changing treatment landscape in first line non-small cell lung cancer.

What is the key exhibit attached to Immutep’s (IMMP) Form 6-K?

The key exhibit is titled “Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer.” It signals scientific communication related to first line non-small cell lung cancer.

Which disease area does Immutep (IMMP) emphasize in this Form 6-K?

Immutep emphasizes first line non-small cell lung cancer. The attached exhibit describes two posters at ESMO Congress 2025 that focus on this disease area and the evolving treatment landscape for patients starting therapy.

What event is associated with Immutep’s (IMMP) Form 6-K exhibit?

The exhibit is associated with ESMO Congress 2025. Immutep highlights two posters to be presented there, underscoring its focus on the changing treatment landscape in first line non-small cell lung cancer.

Who signed Immutep’s (IMMP) Form 6-K report?

The Form 6-K was signed on behalf of Immutep Limited by Chief Executive Officer Marc Voigt. His electronic signature confirms the company’s authorization of the information furnished in connection with the ESMO Congress 2025 posters.